Upstream Bio (UPB) Common Equity (2023 - 2026)

Upstream Bio's Common Equity history runs 4 years deep, the most recent figure standing at $304.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 31.78% year-over-year to $304.0 million; the TTM figure through Mar 2026 stood at $304.0 million (down 31.78% YoY), while the FY2025 annual figure was $339.8 million, down 27.69% from the prior year.
• Common Equity for Q1 2026 stood at $304.0 million, down from $339.8 million in the prior quarter.
• The five-year high for Common Equity was $469.9 million in Q4 2024, with the low at -$160.3 million in Q3 2024.
• The 4-year median for Common Equity is $304.0 million (2026), against an average of $151.9 million.
• Peak annual rise in Common Equity reached 481.6% in 2024, while the deepest fall reached 42.87% in 2024.
• Upstream Bio's Common Equity stood at -$123.1 million in 2023, then soared by 481.6% to $469.9 million in 2024, then slipped by 27.69% to $339.8 million in 2025, then slipped by 10.53% to $304.0 million in 2026.
• Business Quant data shows UPB's Common Equity at $304.0 million in Q1 2026, $339.8 million in Q4 2025, and $378.6 million in Q3 2025.